Literature DB >> 16035731

Molecular analysis of the p27/kip1 gene in breast cancer.

Hatice Tigli1, Nur Buyru, Nejat Dalay.   

Abstract

BACKGROUND: Genetic polymorphisms and mutations of the genes involved in tumorigenesis may determine individual susceptibility for cancer. The p27/Kip1 protein belongs to the family of cyclin-dependent kinase-inhibitory proteins, which are negative regulators of cell-cycle progression. Reduced protein levels of p27/Kip1 have been reported in numerous human cancers including breast cancer. METHODS AND
RESULTS: p27 gene mutations and the codon 109 polymorphism were investigated in breast cancer patients by single strand conformation polymorphism analysis, PCR-restriction fragment length polymorphism analysis and DNA sequencing. Mutations were identified in 2 of 24 breast tumor samples. One G-->A transition resulting in a silent mutation and a single base deletion resulting in a nonsense mutation were detected in one patient. Another breast cancer sample harbored a T-->A transition at codon 159. An association between the codon 109 B allele and breast cancer was observed.
CONCLUSION: Our study indicates that mutational alterations in the p27 gene are rare in human breast cancer. The codon 109 B allele is associated with high-grade tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16035731     DOI: 10.2165/00066982-200509010-00003

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  32 in total

Review 1.  Advances in the molecular genetics of gliomas.

Authors:  M Nagane; H J Huang; W K Cavenee
Journal:  Curr Opin Oncol       Date:  1997-05       Impact factor: 3.645

2.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.

Authors:  C Catzavelos; N Bhattacharya; Y C Ung; J A Wilson; L Roncari; C Sandhu; P Shaw; H Yeger; I Morava-Protzner; L Kapusta; E Franssen; K I Pritchard; J M Slingerland
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Sequence requirement for nuclear localization and growth inhibition of p27Kip1R, a degradation-resistant isoform of p27Kip1.

Authors:  Katsuya Hirano; Ying Zeng; Mayumi Hirano; Junji Nishimura; Hideo Kanaide
Journal:  J Cell Biochem       Date:  2003-05-01       Impact factor: 4.429

4.  p27/Kip1 mutation found in breast cancer.

Authors:  K S Spirin; J F Simpson; S Takeuchi; N Kawamata; C W Miller; H P Koeffler
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

Review 5.  Inhibitors of mammalian G1 cyclin-dependent kinases.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1995-05-15       Impact factor: 11.361

Review 6.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

7.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

8.  C-erbB2, p27 and G1/S aberrations in human primary breast cancer.

Authors:  Martin Lodén; Frans Perris; Niels Hilmer Nielsen; Stefan O Emdin; Göran Landberg
Journal:  Anticancer Res       Date:  2003 May-Jun       Impact factor: 2.480

9.  Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.

Authors:  L Xu; D Sgroi; C J Sterner; R L Beauchamp; D M Pinney; S Keel; K Ueki; J L Rutter; A J Buckler; D N Louis
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

10.  Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.

Authors:  A A Ferrando; M Balbín; A M Pendás; F Vizoso; G Velasco; C López-Otín
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

View more
  8 in total

1.  Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer.

Authors:  Guang Chen; Na Yang; Xiang Wang; Si-Yuan Zheng; Yi Chen; Lin-Jiang Tong; Yi-Xue Li; Ling-Hua Meng; Jian Ding
Journal:  J Mol Med (Berl)       Date:  2010-05-28       Impact factor: 4.599

2.  Association of CDKN1B gene polymorphisms with susceptibility to breast cancer: a meta-analysis.

Authors:  Heping Xiang; He Li; Weiwei Ge; Weidong Wu; Ming Gao; Wei Wang; Lei Hong; Datong Jiang; Changle Zhang
Journal:  Mol Biol Rep       Date:  2013-11       Impact factor: 2.316

3.  Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.

Authors:  Zhong-Ming Jia; Yan Liu; Shou-Yong Cui
Journal:  Tumour Biol       Date:  2014-02-13

4.  Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts.

Authors:  Xiao-Fei Ding; Dong-Qing Yin; Qian Chen; Hua-Yuan Zhang; Jun Zhou; Guang Chen
Journal:  Tumour Biol       Date:  2015-03-07

5.  A study to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma.

Authors:  Komala Pillay; Heather McCleod; Runjan Chetty; Pauline Hall
Journal:  World J Surg Oncol       Date:  2011-03-16       Impact factor: 2.754

6.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

7.  The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma.

Authors:  Mario Capasso; Lee D McDaniel; Flora Cimmino; Andrea Cirino; Daniela Formicola; Mike R Russell; Pichai Raman; Kristina A Cole; Sharon J Diskin
Journal:  J Cell Mol Med       Date:  2017-06-30       Impact factor: 5.310

8.  CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.

Authors:  Davide Viotto; Francesca Russo; Ilaria Anania; Ilenia Segatto; Gian Luca Rampioni Vinciguerra; Alessandra Dall'Acqua; Riccardo Bomben; Tiziana Perin; Martina Cusan; Monica Schiappacassi; Lorenzo Gerratana; Sara D'Andrea; Francesca Citron; Filippo Vit; Lorena Musco; Maria Chiara Mattevi; Giorgia Mungo; Milena S Nicoloso; Maura Sonego; Samuele Massarut; Roberto Sorio; Luigi Barzan; Giovanni Franchin; Giorgio Giorda; Emilio Lucia; Sandro Sulfaro; Vittorio Giacomarra; Jerry Polesel; Federica Toffolutti; Vincenzo Canzonieri; Fabio Puglisi; Valter Gattei; Andrea Vecchione; Barbara Belletti; Gustavo Baldassarre
Journal:  J Pathol       Date:  2020-12-04       Impact factor: 9.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.